FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386893818> ?p ?o ?g. }

• W4386893818 endingPage "1414" @default.
• W4386893818 startingPage "1414" @default.
• W4386893818 abstract "Background: Pompe disease is a lysosomal storage disease characterised by skeletal and respiratory muscle weakness. Since 2006, enzyme replacement therapy (ERT) with alglucosidase alfa has been available. ERT significantly improves the prognosis of patients with Pompe disease. The effect of high antibody titres on treatment response in adults with late-onset Pompe disease (LOPD) remains unclear but may contribute to interpatient variation. We therefore conducted a systematic review on this subject. Methods: A systematic search was performed in Embase, Medline Ovid, Web of Science, Psych Info Ovid, Cochrane (Clinical Trials only), and Google Scholar (random top-200). Articles were included if they involved adults with LOPD treated with alglucosidase alfa and mentioned anti-rhGAA antibodies or antibody titres. In addition, articles mentioning dosages different from the standard recommended dosage were included. Results: Our literature search retrieved 2562 publications, and 17 fulfilled our selection criteria, describing 443 cases. Seven publications reported on anti-rhGAA antibody titres on a group level, with the percentage of patients with a high titre as defined in the included articles ranging from 0–33%. Six publications reported on the effect of anti-rhGAA antibody titre on clinical course, and four found no correlation. Two studies reported a negative effect on treatment. The first study found a greater improvement in Medical Research Council (MRC) score in patients with no detectable antibody titre. In the second study, a patient discontinued ERT due to a declining neuromuscular state as a result of high anti-rhGAA antibody titres. Seven publications reported on 17 individual patients with a high antibody titre (range 1:12,800–1:3,906,250). In only two cases were high-sustained neutralising antibodies reported to interfere with treatment efficacy. Conclusions: No clear effect of anti-rhGAA IgG antibodies on treatment response could be established for the majority of LOPD patients with a high antibody titre. In a minority of patients, a clinical decline related to (possible) interference of anti-rhGAA antibodies was described." @default.
• W4386893818 created "2023-09-21" @default.
• W4386893818 creator A5006864097 @default.
• W4386893818 creator A5020166340 @default.
• W4386893818 creator A5030669499 @default.
• W4386893818 creator A5068920949 @default.
• W4386893818 creator A5072128812 @default.
• W4386893818 creator A5085873875 @default.
• W4386893818 date "2023-09-19" @default.
• W4386893818 modified "2023-10-01" @default.
• W4386893818 title "Are Anti-rhGAA Antibodies a Determinant of Treatment Outcome in Adults with Late-Onset Pompe Disease? A Systematic Review" @default.
• W4386893818 cites W1968892076 @default.
• W4386893818 cites W1973735640 @default.
• W4386893818 cites W1982733872 @default.
• W4386893818 cites W1984182083 @default.
• W4386893818 cites W1986473814 @default.
• W4386893818 cites W1988793208 @default.
• W4386893818 cites W1992387789 @default.
• W4386893818 cites W1994468264 @default.
• W4386893818 cites W1996169715 @default.
• W4386893818 cites W1997306226 @default.
• W4386893818 cites W2013759235 @default.
• W4386893818 cites W2022749609 @default.
• W4386893818 cites W2025560131 @default.
• W4386893818 cites W2030054541 @default.
• W4386893818 cites W2035877771 @default.
• W4386893818 cites W2037050042 @default.
• W4386893818 cites W2046218561 @default.
• W4386893818 cites W2047627643 @default.
• W4386893818 cites W2055737319 @default.
• W4386893818 cites W2056011100 @default.
• W4386893818 cites W2075051827 @default.
• W4386893818 cites W2076454500 @default.
• W4386893818 cites W2084276666 @default.
• W4386893818 cites W2091721067 @default.
• W4386893818 cites W2091777991 @default.
• W4386893818 cites W2091858933 @default.
• W4386893818 cites W2094188127 @default.
• W4386893818 cites W2095643828 @default.
• W4386893818 cites W2111298986 @default.
• W4386893818 cites W2130528924 @default.
• W4386893818 cites W2133992969 @default.
• W4386893818 cites W2139601009 @default.
• W4386893818 cites W2143609092 @default.
• W4386893818 cites W2156098321 @default.
• W4386893818 cites W2159490726 @default.
• W4386893818 cites W2166508127 @default.
• W4386893818 cites W2346606989 @default.
• W4386893818 cites W2460234981 @default.
• W4386893818 cites W246286872 @default.
• W4386893818 cites W2469663448 @default.
• W4386893818 cites W2484045732 @default.
• W4386893818 cites W2548922080 @default.
• W4386893818 cites W2601192680 @default.
• W4386893818 cites W2767691022 @default.
• W4386893818 cites W2891145080 @default.
• W4386893818 cites W2921845178 @default.
• W4386893818 cites W2940078382 @default.
• W4386893818 cites W2941909882 @default.
• W4386893818 cites W2944148921 @default.
• W4386893818 cites W2947475941 @default.
• W4386893818 cites W2960648360 @default.
• W4386893818 cites W2963890606 @default.
• W4386893818 cites W2981219681 @default.
• W4386893818 cites W3033140642 @default.
• W4386893818 cites W3211462560 @default.
• W4386893818 cites W3213397729 @default.
• W4386893818 cites W4206166406 @default.
• W4386893818 cites W4210466003 @default.
• W4386893818 cites W4210550198 @default.
• W4386893818 cites W4226422526 @default.
• W4386893818 cites W4294215472 @default.
• W4386893818 cites W4296259680 @default.
• W4386893818 doi "https://doi.org/10.3390/biom13091414" @default.
• W4386893818 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37759814" @default.
• W4386893818 hasPublicationYear "2023" @default.
• W4386893818 type Work @default.
• W4386893818 citedByCount "0" @default.
• W4386893818 crossrefType "journal-article" @default.
• W4386893818 hasAuthorship W4386893818A5006864097 @default.
• W4386893818 hasAuthorship W4386893818A5020166340 @default.
• W4386893818 hasAuthorship W4386893818A5030669499 @default.
• W4386893818 hasAuthorship W4386893818A5068920949 @default.
• W4386893818 hasAuthorship W4386893818A5072128812 @default.
• W4386893818 hasAuthorship W4386893818A5085873875 @default.
• W4386893818 hasBestOaLocation W43868938181 @default.
• W4386893818 hasConcept C126322002 @default.
• W4386893818 hasConcept C159654299 @default.
• W4386893818 hasConcept C187212893 @default.
• W4386893818 hasConcept C203014093 @default.
• W4386893818 hasConcept C2779134260 @default.
• W4386893818 hasConcept C2779473830 @default.
• W4386893818 hasConcept C2779969927 @default.
• W4386893818 hasConcept C535046627 @default.
• W4386893818 hasConcept C55493867 @default.
• W4386893818 hasConcept C71924100 @default.
• W4386893818 hasConcept C86803240 @default.
• W4386893818 hasConcept C95190672 @default.

• next